• Consumer sell-through surpassed 1 million boxes of Activated Probiotics
• Activated Probiotics is the fastest-growing probiotic brand in Australian pharmacy
• Fullscript Canada national launch commenced, opening North America's largest practitioner distribution channel

Biome Australia Ltd (ASX: BIO) has reported its Appendix 4C and Activity Report for the quarter ended 31 March 2026. Key highlights include:- Consumer sell-through surpassed 1 million boxes of Activated Probiotics on a rolling 12-month basis during Q3 FY26, a company first confirmed by independent pharmacy scan data.- Biome is on track to deliver its 100 millionth dose of Activated Probiotics through community pharmacy and the healthcare practitioner channel within FY26.- Based on independent pharmacy scan data, Activated Probiotics is currently reported as the fastest-growing probiotic brand in Australian community pharmacy over the rolling 12 months, with Biome Daily approaching the number one probiotic product.- The Fullscript Canada national launch commenced in Q3, opening North America's largest practitioner distribution channel to Activated Probiotics.- The company continues to expect FY26 to be profitable, subject to normal trading conditions.- The BMB18 human clinical trial at La Trobe University is due to commence in Q4, enrolling 240 participants. Biome has also lodged a patent application for BMB18, a significant milestone in the company's intellectual property strategy.- International distribution across New Zealand, Canada, Ireland and the United Kingdom continued to develop, with the Fullscript Canada launch and other international markets expected to provide significant diversification on the domestic sales base over time.

The company continues to expect FY26 to be profitable, subject to normal trading conditions.

Biome is well positioned heading into Q4 FY26, with a more active respiratory season beginning to emerge, the company's largest-ever brand campaign now in market, and the Fullscript Canada launch underway. The company has built this business through challenging economic conditions and continued to manage significant growth throughout, reflecting the trust practitioners place in the evidence and the confidence patients place in their practitioners and Biome's products.